Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation.

Management Team

    • Zami Aberman
    • Chairman & Co-CEO
    • Zami Aberman joined Pluristem in September 2005, and redirected the Company's strategy towards cellular therapeutics to become one of the global leaders in the industry. Mr. Aberman's vision to use the maternal portion of the placenta as a cell source for Pluristem’s products, combined with Pluristem's 3D culturing technology, led to the development of the Company's unique therapies. In 2013 the World Stem Cells Regenerative Medicine Congress ranked Mr. Aberman as one of the 50 most influential people in the stem cells space. Prior to Pluristem, Mr. Aberman had a 30 year career as a senior executive in the high-tech industry with multiple companies in Israel, the U.S., Europe, Japan and Korea. Previous roles include Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP; Director of Ori Software Ltd., a company involved in data management; President and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems for the microelectronics industry; President and CEO of Netect Ltd., a company specializing in the field of internet security software; Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing; Chairman of Display Inspection Systems Inc., a company specializing in laser based inspection machines; and President and CEO of Robomatix Technologies Ltd. (RBMXF.OB). In addition to his current role at Pluristem, Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.
    • Yaky Yanay
    • Co-CEO and President
    • Yaky Yanay was appointed as our President from February 2014 and as our Co-CEO from March 2017. Mr. Yanay served as our Chief Financial Officer from November 2006 until February 2014 and from February 2015 until March 2017. He also served as our Chief Operating Officer from February 2014 until March 2017. Until February 2014, he also served as our Secretary since November 2006, and Executive Vice President since March 2013. Before joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision Systems Ltd., a public company. Prior to that Mr. Yanay served as manager of audit groups of the technology sector at Ernst & Young Israel. Mr. Yanay is Co-Chairman of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israel’s high tech and life science industries. Yanay is representing Israel’s life sciences industry and has served on the Board of Directors of IATI for the past four years. Mr. Yanay also founded and served as Chairman of the “The Life Science Forum”. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting and is a Certified Public Accountant in Israel.
    • Efrat Livne-Hadass
    • VP Human Resources
    • Efrat Livne-Hadass joined Pluristem in 2007 and is responsible for all aspects of Human Resources management, including recruitment, professional training, and well-being. Prior to joining Pluristem and during the years 2001-2005, Ms. Livne-Hadass held the position of Human Resources Manager at Elbit Vision Systems, a company engaged in automatic optical inspection, located in Yokneam, Israel. While holding that position, she was involved in some major challenges and change processes which the company was going through, including managing HR in a small yet global public company. Ms. Livne-Hadass holds an Executive M.A. for Human Resources managers from the department of Labor Studies, Tel-Aviv University and a B.Sw. degree from the Haifa University, majoring in public healthcare services.
    • Hillit Mannor Shachar, M.D.
    • VP Business Development
    • Hillit Mannor Shachar, M.D., joined Pluristem in October 2013 as VP of Business Development. Prior to joining Pluristem, Dr. Shachar had over ten years' experience in both business development and corporate development having worked and consulted at companies including West Pharmaceutical Services, Nektar Therapeutics, Orex Computer Radiography (acquired by Kodak) and Transpharma Medical. Dr. Shachar worked at Apax Partners as a healthcare associate and at Deloitte Israel as a consultant in their life science practice. Dr. Shachar graduated from Northwestern University's Honors Program in Medical Education and holds a B.A. and M.D. from there. In addition, she holds a M.B.A. from Kellogg Recanati Executive Program and an MSFS from Georgetown University.
    • Erez Egozi
    • CFO
    • Mr. Erez Egozi was appointed Chief Financial Officer in March 2017, and as Secretary in September 2015. Prior to his appointment as CFO, Mr. Egozi was our Vice President of Finance from March 2015 until March 2017. Before Joining Pluristem, from 2007 to 2015, Mr. Egozi held several senior financial positions at Verint Systems Inc (Nasdaq:VRNT), including as senior director of finance - worldwide finance controller of Verint's Communications and Cyber Intelligence Solutions division. From 2003 to 2007, Mr. Egozi held several financial positions at Intel Corporation (Nasdaq:INTC). From 2000 to 2003, Mr Egozi served as an auditor in the high tech technology sector at Deloitte & Touche.  Mr. Egozi holds a bachelor's degree in economics and accounting from Beer-Sheva University, and a M.A. degree in law from Bar-Ilan University, and is a certified public accountant in Israel.
    • Esther Lukasiewicz Hagai, M.D., Ph.D.
    • VP Clinical & Medical Affairs
    • Dr. Lukasiewicz-Hagai has twelve years' experience in Drug development. She joins Pluristem from Teva Global R&D, where she was Director, Clinical Program Leader, leading the global clinical development of multiple biosimilars and innovative drugs in various Oncologic and Neuropsychiatric indications. She previously worked at Gertner Institute for Epidemiology and Health Policy Research (Sheba Medical Center, Tel Hashomer) where she was responsible of multiple national and US-Israeli clinical trials in Orthopedic and Hemato-Oncologic indications. Dr Lukasiewicz-Hagai holds a M.D. and a Medical Residency in Public Health and Social Medicine from Necker-Enfants Malades Paris V School of Medicine In addition, she holds a Master of Methodology and Statistics in Clinical Research and a M. Med. Sc. in Biostatistics and Epidemiology from Paris XI as well as a Ph.D. in Biostatistics from Bar-Ilan University.
    • Sagi Moran, M.B.A.
    • VP Operations
    • Sagi Moran, joined Pluristem in June 2014 as VP of Operations. Prior to joining Pluristem, Mr. Moran served as the CTO for LASER medical device startup AxonoGen Ltd., and as COO for NovoXel Ltd. Mr. Moran established a medical division for Qualitest Group Ltd., the largest engineering and testing services group for the medical industry in Israel. The division provides services for pharmaceutical and medical companies, such as TEVA, PHILIPS healthcare, GE, UltraShape, Given Imaging and others. Prior to that Mr. Moran served for 10 years in Lumenis Ltd. In key global managerial position in R&D and Operations. Mr. Moran holds a Master of Business Administration (MBA) from Recanati Executive MBA program at Tel-Aviv University, and a bachelor’s degree in Information Systems from Haifa University.
    • Orly Amiran
    • VP Quality Assurance
    • Orly Amiran holds a master degree in Quality Assurance from the Technion and a B.Sc. in Pharmacy from the Hebrew University. She has worked in the pharmaceutical industry since 2001 and has extensive experience in Quality Assurance management in global companies which market drugs to the European market and to North America. Prior to joining Pluristem Orly held the positions of Quality Assurance Manager at TEVA and Compliance Manager at Taro. She played a central role in successful regulatory agencies inspections in both positions. Ms. Orly Amiran brings with her to Pluristem a vast experience and knowledge on GMP, quality regulations and the corresponding industry best practices.
    • Racheli Ofir, Ph.D., MA. Law
    • VP Research & Intellectual Property
    • Racheli Ofir Joined Pluristem in 2007, serves as Vice President of research and intellectual property. The Research Department examines the various cells developed by the company, the properties of those cells and their mechanisms of action by using molecular methods and animal models to test the safety and efficacy. The IP department is responsible for intellectual property strategy development as well as the research that supports the IP. Dr. Ofir is responsible for leading projects involving the characterization of PLX cells, Pluristem's leading placenta derived cell product candidate, including evaluating the biological activity of the cells in in-vitro and animal studies. She is responsible for the studies which determines the safety profile and pharmacokinetics of PLX cells. In addition, she is in charge of all pre-clinical aspects of the PLX regulatory process and for the communications with the relevant regulatory authorities (FDA, EMA and PEI). Dr. Ofir is also responsible for applying and prosecuting over ten patent families filed worldwide, a co-inventor on five patent applications and the co-author of numerous peer reviewed articles. Dr. Ofir earned her Ph.D. from the Technion, Israel institute of technology, where she investigated Telomeric position effects on gene expression and DNA replication in Human cells. She did her postdoctoral fellowship at the Technion in molecular embryology investigating genes involved in early development of vertebrates' nervous system. Dr. Ofir has extensive research experience in molecular cell biology, embryology and cytogenetics as well as broad professional experience in the field of human cell therapy.
    • Lior Raviv
    • VP Development
    • Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development. Prior to that Mr. Raviv served as Process development engineer and Projects manager & Product development Team leader at Pluristem. Prior to joining Pluristem and during the years 2010-2011, Mr Raviv held the position of R&D Analytical Researcher at Teva Pharmaceutical Industries. Mr. Raviv holds a M.Med.Sec in pharmacology from the Ben Gurion University and a B.S.c, in Biotechnology engineering from the Ben Gurion University.
    • Karine Kleinhaus, M.D., M.P.H.
    • Divisional VP, North America
    • Karine Kleinhaus, M.D., M.P.H., is Divisional Vice President, North America at Pluristem Therapeutics. She has worked with multiple public and private biotechnology companies, and prior to that she was an Assistant Professor in the Departments of Obstetrics and Gynecology and Psychiatry at the NYU School of Medicine. At NYU, Dr. Kleinhaus conducted medical research funded under a multi-year NIH grant. She published more than 25 papers in leading peer-reviewed journals such as the Annals of the New York Academy of Science, American Journal of Medical Genetics, and the American Journal of Epidemiology. Before that Dr. Kleinhaus practiced obstetrics and then completed two fellowships at Columbia University. Dr. Kleinhaus received her medical degree from Tel Aviv University, earned a Master of Public Health from Columbia’s Mailman School of Public Health, and a bachelor’s degree, cum laude, from Princeton University.

Board

  • Zami Aberman
    • Mr. Zami Aberman joined Pluristem in September 2005, and redirected the Company's strategy towards cellular therapeutics to become one of the global leaders in the industry. Mr. Aberman's vision to use the maternal portion of the placenta as a cell source for Pluristem’s products, combined with Pluristem's 3D culturing technology, led to the development of the Company's unique therapies. In 2013 the World Stem Cells Regenerative Medicine Congress ranked Mr. Aberman as one of the 50 most influential people in the stem cells space. Prior to Pluristem, Mr. Aberman had a 30 year career as a senior executive in the high-tech industry with multiple companies in Israel, the U.S., Europe, Japan and Korea. Previous roles include Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP; Director of Ori Software Ltd., a company involved in data management; President and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems for the microelectronics industry; President and CEO of Netect Ltd., a company specializing in the field of internet security software; Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing; Chairman of Display Inspection Systems Inc., a company specializing in laser based inspection machines; and President and CEO of Robomatix Technologies Ltd. (RBMXF.OB). In addition to his current role at Pluristem, Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.
  • Yaky Yanay
    • Mr. Yaky Yanay was appointed as Pluristem’s President and Chief Operating Officer in February 2014 and prior to that served as Pluristem’s Chief Financial Officer and Secretary since November 2006, and Executive Vice President since March 2013. Before joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision Systems Ltd., a public company. Prior to that Mr. Yanay served as manager of audit groups of the technology sector at Ernst & Young Israel. Mr. Yanay is Co-Chairman of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israel’s high tech and life science industries. Yanay is representing Israel’s life sciences industry and has served on the Board of Directors of IATI for the past three years. Mr. Yanay also founded and served as Chairman of the “The Life Science Forum”. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting and is a Certified Public Accountant in Israel.
  • Mark Germain
    • Mr. Mark Germain has served as a Director on the Board of Directors since May 17, 2007. For more than the past five years, Mr. Germain has been a merchant banker serving primarily the biotech and life sciences industries. He has been involved as a founder, director, Chairman of the Board, and/or investor in over twenty companies in the biotech field, and assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions. He graduated New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law. From 1986 to 1991 he served in senior executive capacities, including as president of a public company that was sold in 1991, at which time he entered the biotech field. In addition to being Co-Chairman at Pluristem, Mr. Germain is a director of the following publicly traded companies: Wellford Real Properties, Inc., Stem Cell Innovations, Inc., and Collexis Holdings, Inc. He is also a co-founder and director of a number of private companies in the biotechnology field.
  • Hava Klemperer Meretzki
    • Mrs. Hava Klemperer Meretzki, Adv. is a partner in the law firm of Ben-Noun Meretzki in Haifa, Israel. She specializes in civil, trade and labor law and is presently Vice-Chairman for the National Council of the Israel Bar Association. She previously was a Director of the Israel Electric Company. Ms. Meretzki received a Bachelors Degree in Law from the Hebrew University in 1991, and in 1992, was admitted to the Israel Bar Association.
  • Doron Shorrer
    • Mr. Doron Shorrer (CPA, Israel) was Chairman of the Board of Phoenix Insurance Company, one of the largest insurance companies in Israel and Mivtachim Pension Benefit Group, the largest pension fund in Israel, managing $15 billion. Before assuming these positions, Mr. Shorrer held senior appointments that included: Arbitrator at the Claims Resolution Tribunal for Dormant Accounts in Switzerland; Economic and Financial Advisor, Commissioner of Insurance and Capital Markets for the State of Israel; Member of the Board of Directors of "Nechasim" of the State of Israel; Member of the Committee for the Examination of Structural Changes in the Capital Market (The Brodet Committee); General Director of the Ministry of Transport; Co-Founder and Director of an accounting firm having three branches (Jerusalem, Tel-Aviv, Haifa); Member of the Lecture Staff of the Amal School Chain; Chairman of a Public Committee for Telecommunications; and Economic Consultant to the Ministry of Energy. Among many areas of expertise, Mr. Shorrer formulates, implements and administers business planning in the private and institutional sector. Additionally, Mr. Shorrer consults on economic, accounting and taxation issues to a large audience, ranging from private concerns to government ministries. Mr. Shorrer holds a B.A. in Economics and Accounting and an M.A. in Business Administration, with a specialization in finance and banking from the Hebrew University of Jerusalem. He is a Certified Public Accountant (ISR).
  • Isaac Braun
    • Mr. Isaac Braun was appointed a Director of Pluristem on July 6, 2005. Mr. Braun is a business veteran with entrepreneurial, industrial and manufacturing experience. He has been a co-founder and board member of several hi-tech start-ups in the areas of e-commerce, security, messaging, search engines and biotechnology. Mr. Braun advises private companies on raising financing and business development.
  • Israel Ben Yoram
    • Mr. Israel Ben-Yoram was appointed a director of Pluristem on January 26, 2005. Mr. Ben-Yoram has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel from 1985 to the present. This accounting firm currently employs over 15 employees in the field of auditing, consulting, and associated projects. Since 1992, Mr. Ben-Yoram has served as a shareholder and the head director of Mor, Ben-Yoram Ltd., a private company in Israel, in parallel with the operation of the Mor, Ben-Yoram and Partners accounting firm. This company provides management services, economic consulting services and other professional services to businesses. Mr. Ben-Yoram received a B.A. in accounting from the University of Tel Aviv, an M.A. in Economics from the Hebrew University of Jerusalem, an L.L.B. and an M.B.A. from Tel Aviv University and an L.L.M. from Bar-Ilan University.
  • Nachum Rosman
    • Mr. Nachum Rosman is an expert in finance, management and organization. He has held Chief Executive and CFO positions in Israel, USA and England. He has operated in high-tech global companies in software and business. In these jobs he was responsible for finance management, fund-raising, acquisitions, technology sales, preparation of financial reports for due diligences, etc. Mr. Rosman serves as a consultant to start-up companies in financing, strategy and reorganization. He serves as the CEO of Multiview Ltd, a company he co-founded in 1999. He serves as a director at Zoomix data mastering and Knolan. Mr. Rosman was a director actively involved in the sale of New Dimension Ltd. to B.M.C. Inc. for $ 675 million. Prior to that he held a Co-CEO position in R.T.S. Ltd. (Virinet Ltd.), where he participated in the IPO on NASDAQ.
  • Moria Kwiat
    • Dr. Moria Kwiat is a Research Fellow in the Department of Materials and NanoSciences, Faculty of Chemistry at Tel Aviv University. During her studies she has gained a broad scientific experience in inter-disciplinary fields, and currently she is working on the development of a new generation of biosensors based on nano-materials. Mrs. Kwiat holds a B.Sc. and M.Sc. in Biotechnology from the Department of Molecular Microbiology and Biotechnology at Tel Aviv University, and a Ph.D. in Nano-Biotechnology from the Faculty of Exact Sciences at Tel Aviv University.